300355-14-0

Upstream product

• 64-17-5 ethanol 
• 87776-75-8 (3-chloro-4-methylsulfanyl-phenyl)-acetic acid 
• 300355-13-9 acetoxy(3-chloro-4-methylsulfanylphenyl)acetic acid ethyl ester 
• 300355-12-8 (3-chloro-4-methylsulfanyl-phenyl)hydroxyacetic acid ethyl ester 
• 300355-11-7 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid ethyl ester 
• 17733-22-1 2-chlorothioanisole 
• 32248-43-4 samarium diiodide 

Downstream Products

• 300355-15-1 2-(3-chloro-4-methylsulfanylphenyl)-3-cyclopentylpropionic acid ethyl ester 
• 952517-42-9 2-(3-chloro-4-(methylsulfonyl)phenyl)-3-(8,8-dimethyl-6,10-dioxaspiro[4.5]-decan-2(R)-yl)propanoic acid 
• 300355-16-2 2-(3-chloro-4-methylsulfanylphenyl)-3-cyclopentylpropionic acid 
• 300355-17-3 2-(3-chloro-4-methylsulfanylphenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide 
• 952517-41-8 C₂₀H₂₇ClO₄S 
• 1080060-94-1 ethyl [3-chloro-4-(methylsulfonyl)phenyl]acetate 

Relevant academic research and scientific papers

Chlorotrimethylsilane and Sodium Iodide: A Useful Combination for the Regioselective Deoxygenation of Arylalkyl-α-Diketones

An efficient regioselective deoxygenation of arylalkyl-1,2-diketones by the couple trimethylsilylchloride/sodium iodide has been reported. In all cases, the deoxygenation takes place on the carbonyl group (Cα=O) proximal to the aromatic ring in methylene chloride at room temperature in good yields, furnishing a series of variously functionalized alkylbenzylketones. A large range of functional groups were well tolerated on the ortho-, meta- and para-positions by this mild process regardless of their electronic effects, demonstrating the general character of the present methodology. The trimethylsilylchloride/sodium iodide reducing process was also successfully applied to reduce α-ketoacid and α-ketoester substrates. (Figure presented.).

Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.

NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention has a glucokinase activity, and is useful as a medicament such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like.

CRYSTALLINE ISOPROPANOL SOLVATE OF GLUCOKINASE ACTIVATOR

Provided is a crystalline IPA solvate of 2(R)-(3-chloro-4-methanesulfonyl-phenyl)- 3-((R)-3-oxo-cyclopentyl)-N-pyrazin-2-yl-propionamide as a glucokinase activator which increases insulin secretion in the treatment of, for example, type II diabetes.

Heteroaromatic glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.